WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , Scientific Journal Impact Factor (SJIF) , IFSIJ Measure of Journal Quality , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , Research Publication Rating and Indexing , Doi-Digital Online Identifier , ISSN National Centre , Zenodo Indexing , International CODEN Service, USA , 

ISSN 2457-0400

Impact Factor  :  6.711

WJAHR Citation

  All Since 2020
 Citation  105  60
 h-index  4  4
 i10-index  3  2

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: OCTOBER ISSUE PUBLISHED

    OCTOBER 2025 Issue has been successfully launched on OCTOBER 2025.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR October 2025 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

Best Article Awards

World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

INNOVATIVE PERSPECTIVES OF THE UTILIZATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR MANAGING OBESE POLYCYSTIC OVARY SYNDROME (PCOS) WOMEN & TREATMENT OFNON PCOS OBESE INFERTILE WOMEN FORIMPROV ING PREGNANCY & LIVE BIRTH RATES - A SHORT COMMUNICATI

*Dr. Kulvinder Kochar Kaur

ABSTRACT

Having comprehensively reviewed earlier the Polycystic ovary syndrome (PCOS) classification, methodologies for weight reduction inclusive of targeting brown adipose tissue (BAT) in PCOS and in routine obesityinclusive of i) Orlistat (Xenical) to ii)Combinational Agents -a)QsymiaTM (phentermine hydrochloride/ delayed release topiramate beads (TPM), b) Contrave(Bupropion/ Naltrexone)/just topiramate which wasfollowed by GLP1R Agonists -Liraglutide3mg. Nonetheless, till 2019 maximum pharmacotherapy did not yield sustenance of weight reduction and did notprove to be efficacious over 1-5kg reduction for greater than 3-6mths. The only drug that illustrated some promise were believed to be thylakoids. Therefore, a single drug in which agonism for the receptors of glucagon, glucagon like peptide1 (GLP1), glucose dependent insulinotropic polypeptide (GIP) was combined in view of mechanistic modes of bariatric surgery (BS) was posited to be through central nervous system(CNS), and certain other GIT hormones for instance GLP1, ghrelin and PYY. Nonetheless, we did not utilize GLP1RAs in women with PCOS, due to expenses, parenteral use, accessiblity nevertheless, we reviewed Obesity and Heart failure with preserved ejection fraction (HFpEF) glucagon like peptide 1(GLP-1)-1 receptor agonist(GLP-1RA), inclusive of long acting GLP-1RA’s for instance liraglutide and, oral semaglutide gets done/day, whereas dulaglutide, exenatideextended release, subcutaneous(s/c) semaglutidedelivery with gets done once weekly. Here we present, the manner GLP1RAs, especially, the latest GLP-1RA’s might prove to be efficacious in obese PCOS women in reference to weight reduction prior to embarking on pregnancy for improving pregnancy rate(PR) & live birth rates(LBR), however greater work is required regarding newer GLP1Ras, since it has been observed newer GLP1Rpossess definitive greater weight reduction efficacy in contrast to liraglutide and other first generationGLP1R prior to undergoing pregnancy, would conclusively aid in escalating the PR and LBR, but needs studying in PCOS effects of semaglutide, Tirzepatide(GLP1+ GIP)) combo as only restrictedly studied.

[Full Text Article] [Download Certificate]